Ultralife (NASDAQ:ULBI) is preparing to release its quarterly earnings on Tuesday, 2026-03-10. Here's a brief overview of what investors should keep in mind before the announcement.

Analysts expect Ultralife to report an earnings per share (EPS) of $0.27.

Ultralife bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Earnings Track Record

In the previous earnings release, the company missed EPS by $0.29, leading to a 0.2% increase in the share price the following trading session.

Here's a look at Ultralife's past performance and the resulting price change:

Market Performance of Ultralife's Stock

Shares of Ultralife were trading at $5.25 as of March 06. Over the last 52-week period, shares are down 8.16%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

Unveiling the Story Behind Ultralife

Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.

Ultralife: A Financial Overview

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: Ultralife displayed positive results in 3 months. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 21.51%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.

Net Margin: Ultralife's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.81% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Ultralife's ROE stands out, surpassing industry averages. With an impressive ROE of -0.89%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Ultralife's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.55% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Ultralife's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.37.

To track all earnings releases for Ultralife visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.